CSAAI 2018 A Midsummer Night's Wheeze

June 29, 2018 to July 1, 2018

This program is designed to teach the busy allergist new medications and techniques for treating allergic diseases. Increasingly, the clinical allergist sees more people with a number of evolving problems including food allergies and sensitivity as well as asthma, mast cell diseases, sinusitis, non-allergic rhinitis and different types and degrees of anaphylaxis. With food allergies, the allergist needs to know the latest advances in oral desensitization including pretreatment with medications as well as diagnosis, management and prevention. Increasingly, asthmatics are being treated by the allergist, not the pulmonologist and they have a new armamentarium of biologics available to use. This program will familiarize allergists with the various new medications and give them the skills needed to optimally individualize treatment based upon the patient’s disease state, medical history and laboratory values including eosinophil counts. The allergist also needs to also know advances in treatment of anaphylaxis in infants and children as well as adults. This program will bring the participant up-to-date on the latest information on treating and preventing allergic illnesses, treating anaphylaxis, sinus disease, non-allergic rhinitis, mastocytosis and mast cell activation syndrome. The program will also discuss asthma prevention via environmental controls as well as asthma medication and treatment strategies.

Accreditation  
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the California Society of Allergy, Asthma and Immunology (CSAAI) .  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 12 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:
This activity is supported in part by an independent medical education grant from Optinose.

Target Audience

Practicing allergists, primary care physicians, and allied health care professionals in the field of allergy and immunology.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize recent advances in understanding and treatment of mastocytosis and mast cell activation syndrome
  • Review the allergenic aspects of the dust mite
  • Recognize the safety issues and efficacy of various asthma treatments in adults
  • Describe the treatment of anaphylaxis in infants and toddlers
  • Explain the use of SLIT in the treatment of allergic rhinitis and asthma
  • Summarize the treatment choices in severe chronic rhinosinusitis
  • Outline the treatment of anaphylaxis when the allergen is a glycolipid
  • Review the protocol for food allergy desensitization
  • Outline the prevention, diagnosis and therapy of food allergies
Additional information
Disclosure: 

CSAAI 2018 A Midsummer Night’s Wheeze
The Westin St. Francisco| San Francisco, CA
June 29-July 1, 2018

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

Cem Akin, MD, PhD – Speaker
Consultant: Novartis, Blueprint

R. Sharon Chinthrajah, MD – Speaker
Advisory Board Member: AstraZeneca, Aimmune Therapeutics

J. Allen Meadows, MD, FACAAI – Speaker
Speaker: Teva, Circassia, The PBL Institute, Pfizer, Optinose
Consultant: Kaleo
Advisory Board Member: ALK

Thomas Platts-Mills, MD, PhD, FRS – Speaker
Support received assays: Thermo Fisher Scientific
Grant recipient: NIH

David P. Skoner, MD – Speaker
Speaker: Greer, Mylan, Merck, ALK
Consultant: Boston Scientific, Optinose 

Arthur Wu, MD – Speaker
Speaker: Intersect ENT

Madeline Ramos, MD – Planner
Speaker – Teva

Raffi Tachdjian, MD – Planner
Speaker: CSL Behring, Shire, Pharming, Alcon, Teva, Circassia
Advisory Board Member: CSL Behring, Shire, Pharming


The following have no relevant financial relationships to disclose:

Evan Walgama, MD – Speaker
Emily Liang, MD – Speaker
Anna Postolova, MD – Speaker
Christina Schwindt, MD – Presenter, Planner
Robert Eitches, MD – Presenter, Planner, Reviewer
Sheila Bonilla, MD, MS – Planner
Karol Anderson – Planner
LanAnh Do, MD – Planner
Marilyn Li, MD – Planner
Sonal Patel, MD – Planner
Vincent Tubiolo, MD – Planner
 

Course summary
Available credit: 
  • 12.00 AMA PRA Category 1 Credit™
  • 12.00 Attendance
Course opens: 
06/29/2018
Course expires: 
07/01/2020
Event starts: 
06/29/2018 - 12:00pm
Event ends: 
07/01/2018 - 11:45am
Cost:
$0.00
Rating: 
0
The Westin St. Francis
San Francisco, CA
United States

Available Credit

  • 12.00 AMA PRA Category 1 Credit™
  • 12.00 Attendance

Accreditation Period

Course opens: 
06/29/2018
Course expires: 
07/01/2020

Price

Cost:
$0.00
Please login or create an account to take this course.